BioCryst Pharmaceuticals Inc. BCRX, +3.50%
shares rallied in the extended session Thursday after the drug maker
said it was starting a clinical trial to test its COVID-19 treatment.
BioCryst shares surged 35% after hours, following a 3.5% rise to close
the regular session at $2.07. The company said it opened a randomized,
double-blind, placebo-controlled clinical trial to test the drug
galidesivir in treating patients with COVID-19. The study, which is
being funded by the U.S. National Institutes of Health’s National
Institute of Allergy and Infectious Diseases, will be conducted in
Brazil, the company said. Many drug companies have recently started development of either COVID-19 treatments or vaccines.
https://www.marketwatch.com/story/biocryst-stock-rallies-on-start-of-coronavirus-drug-study-2020-04-09
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.